Latest News
-

Keeping up with HD research just got easier: Introducing the HDBuzz Trial Tracker
⏱️6 min read | Ever wonder when to expect the next update from a clinical trial for Huntington’s disease? The HDBuzz Trial Tracker puts future updates for HD trials on a clear timeline, with deeper explanations in our articles when you want them.
-

Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
-

What do sheep brains have to do with HD?
How smart are sheep, and why do HD researchers care?
-

Interview: CHDI Management
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
-

CHDI Report: Day 3
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
-

CHDI Report: Day 2
Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD
-

CHDI Report: Day 1
Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene
-

Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way
Anti-nausea drug meclizine protects cells with the HD mutation from death by reducing cellular energy production
-

HDBuzz takes your questions to the annual therapeutics meeting of CHDI
HDBuzz visits Palm Springs to talk with CHDI about the latest HD research. Send us your questions!
-

Welcome to HDBuzz
Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co
-

Memantine in HD: dose is everything
Memantine, a drug already used in Alzheimer’s disease, might help in HD, but a mouse study shows dose is everything.
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Previously featured
-
Keeping up with HD research just got easier: Introducing the HDBuzz Trial Tracker
-
Vaccines and Neurodegeneration: Lessons for Huntington’s Disease?
-
UniQure Secures Type A Meeting with FDA: What This Means for AMT-130
-
Putting Huntington’s disease medications to the test: results from the Neuro-HD trial
-
HDBuzz Is Officially Independent: What This Means, and Why It Matters
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
